Abstract
Synthetic compounds with a tri- and tetra-substituted imidazole scaffold are known as selective inhibitors of the p38 mitogenactivated protein (MAP) kinase responsible for proinflammatory cytokine release. The scope is to review the literature describing their design, synthesis and activity studies. To date a great plethora of crystal structures of p38 in complex with small organic ligands have been published. Cocrystallized ligand information is of particular interest to our review study, i.e. ATP itself, the reference inhibitor SB203580 with its aryl-pyridinyl-imidazoles and related imidazole and pyrimidine-based derivatives. The selective inhibitors bind to the pocket of adenosine 5'-triphoshate (ATP) replacing the latter. The hydrophobic region II, however, is not occupied by the natural binder ATP, but accommodates the pyridine substituents preserving the 4-fluorophenyl ring occupation in pocket I as a prerequisite to gain higher binding selectivity and potency than the reference compound SB203580 (4-[5-(4-fluoro-phenyl)-2-(4-methanesulfinyl-phenyl)-3himidazol- 4-yl]-pyridine). Experimental and computed work is reviewed which evidence that the 2 position of the pyrimidine ring is amenable to the introduction of a side chain and the replacement of pyridine in SB203580 by a pyrimidine ring improves both inhibitory activity and selectivity for p38 over other kinases. All ligands with a pyridyl C2 side chain occupy the hydrophobic pocket II and in some cases a double hydrogen bond is reported between methionine 109 and glycine 110 of the hinge region, following an observed backbone shift. The substituted pyridine ring binds stronger than the two other side chains on the imidazole scaffold.
Keywords: p38α MAP kinase inhibitors, 1, 2, 4, 5-tetrasubstituted imidazoles, 1, 2, 4, 5-tetrasubstituted pyrimidines, 2, 4, 5-trisubstituted or 2-benzyl thiopyrimidines, pyrimidines, 2, 4, 5-trisubstituted, 2-benzyl thiopyrimidines, Synthetic compounds, imidazole scaffold, proinflammatory, cytokine, pyrimidine-based derivatives
Current Medicinal Chemistry
Title: Pharmacophore Design of p38α MAP Kinase Inhibitors with Either 2,4,5-Trisubstituted or 1,2,4,5-Tetrasubstituted Imidazole Scaffold
Volume: 18 Issue: 10
Author(s): T. Scior, D. M. Domeyer, K. Cuanalo-Contreras and S. A. Laufer
Affiliation:
Keywords: p38α MAP kinase inhibitors, 1, 2, 4, 5-tetrasubstituted imidazoles, 1, 2, 4, 5-tetrasubstituted pyrimidines, 2, 4, 5-trisubstituted or 2-benzyl thiopyrimidines, pyrimidines, 2, 4, 5-trisubstituted, 2-benzyl thiopyrimidines, Synthetic compounds, imidazole scaffold, proinflammatory, cytokine, pyrimidine-based derivatives
Abstract: Synthetic compounds with a tri- and tetra-substituted imidazole scaffold are known as selective inhibitors of the p38 mitogenactivated protein (MAP) kinase responsible for proinflammatory cytokine release. The scope is to review the literature describing their design, synthesis and activity studies. To date a great plethora of crystal structures of p38 in complex with small organic ligands have been published. Cocrystallized ligand information is of particular interest to our review study, i.e. ATP itself, the reference inhibitor SB203580 with its aryl-pyridinyl-imidazoles and related imidazole and pyrimidine-based derivatives. The selective inhibitors bind to the pocket of adenosine 5'-triphoshate (ATP) replacing the latter. The hydrophobic region II, however, is not occupied by the natural binder ATP, but accommodates the pyridine substituents preserving the 4-fluorophenyl ring occupation in pocket I as a prerequisite to gain higher binding selectivity and potency than the reference compound SB203580 (4-[5-(4-fluoro-phenyl)-2-(4-methanesulfinyl-phenyl)-3himidazol- 4-yl]-pyridine). Experimental and computed work is reviewed which evidence that the 2 position of the pyrimidine ring is amenable to the introduction of a side chain and the replacement of pyridine in SB203580 by a pyrimidine ring improves both inhibitory activity and selectivity for p38 over other kinases. All ligands with a pyridyl C2 side chain occupy the hydrophobic pocket II and in some cases a double hydrogen bond is reported between methionine 109 and glycine 110 of the hinge region, following an observed backbone shift. The substituted pyridine ring binds stronger than the two other side chains on the imidazole scaffold.
Export Options
About this article
Cite this article as:
Scior T., M. Domeyer D., Cuanalo-Contreras K. and A. Laufer S., Pharmacophore Design of p38α MAP Kinase Inhibitors with Either 2,4,5-Trisubstituted or 1,2,4,5-Tetrasubstituted Imidazole Scaffold, Current Medicinal Chemistry 2011; 18 (10) . https://dx.doi.org/10.2174/092986711795328409
DOI https://dx.doi.org/10.2174/092986711795328409 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biomarkers for VEGF-Targeted Therapy in Renal Cell Carcinoma: Critical Review of Level of Evidence and Up to Date
Recent Patents on Biomarkers Non-Peptidic Inhibitors of Cysteine Proteases
Mini-Reviews in Medicinal Chemistry Adhesion Molecules and Kinases Involved in γ δ T Cells Migratory Pathways:Implications for Viral and Autoimmune Diseases
Current Medicinal Chemistry Sodium Selenite Modulates Global Activation of Proinflammatory M1-like Macrophages, Necroinflammation and M1-like/M2-like Dichotomy at the Onset of Human Type 1 Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets Gene and Cancer Therapy - Pseudorabies Virus: A Novel Research and Therapeutic Tool?
Current Gene Therapy Telomeres and their Role in Aging and Longevity
Current Vascular Pharmacology The Citrus Flavanone Hesperetin Induces Apoptosis in CTCL Cells <i>via</i> STAT3/Notch1/NFκB-Mediated Signaling Axis
Anti-Cancer Agents in Medicinal Chemistry Anticancer Potential of Dietary Natural Products: A Comprehensive Review
Anti-Cancer Agents in Medicinal Chemistry Anti-Tumor Necrosis Factor-Alpha (TNF-α) Treatment Strategies in Crohns Disease
Recent Patents on Inflammation & Allergy Drug Discovery Amyloid A in Serum and Ascitic Fluid as a Novel Diagnostic Marker of Spontaneous Bacterial Peritonitis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Identification of Pharmacological Targets in Amyotrophic Lateral Sclerosis Through Genomic Analysis of Deregulated Genes and Pathways
Current Genomics Chemometric Modeling of 5-Phenylthiophenecarboxylic Acid Derivatives as Anti-Rheumatic Agents
Current Computer-Aided Drug Design Important Anti-Cancer Applications of Protein Based Nanoparticles
Current Proteomics Biological Characteristics and Role of Histamine in Case of Allergic Rhinitis
Medicinal Chemistry Reviews - Online (Discontinued) Phosphodiesterase 4 Inhibitors for the Treatment of Asthma and COPD
Current Medicinal Chemistry Epratuzumab and Blinatumomab as Therapeutic Antibodies for Treatment of Pediatric Acute Lymphoblastic Leukemia: Current Status and Future Perspectives
Current Medicinal Chemistry Preface: Developments in Understanding of Alzheimer Disease
Current Alzheimer Research The Pathology of Alcohol Hangover
Current Drug Abuse Reviews Vanillic Acid and Non-Alcoholic Fatty Liver Disease: A Focus on AMPK in Adipose and Liver Tissues
Current Pharmaceutical Design The TGF-β 1/Foxp3 Regulatory Axis in Immune Self-Tolerance: Implications for Health and Disease
Inflammation & Allergy - Drug Targets (Discontinued)